Seòmar agus comataidhean

The National Cancer Medicines Advisory Group (NCMAG) will review the use of Anastrozole, Tamoxifen and Raloxifene as a preventative treatments for post-menopausal women at a moderate or high risk of breast cancer at a rescheduled meeting in Autumn 2024.

In anticipation of potential NCMAG advice, Scottish Government is considering how these drugs may fit in to a chemoprevention care pathway within NHS Scotland, including patient identification and monitoring.

Scottish Government welcomed the transport to health and social care report from the Mobility and Access Committee (MACS) and agreed to develop a transport to health plan in response.

Progress has been made against the recommendations including bringing more focus and prominence in work with the relevant partners including Regional Transport Partnerships and Health Boards to take forward specific actions and commitments towards better joined up care planning and working.

Recognising the importance of the recommendations, Transport Scotland have included Transport to Health as one of seven thematic workstreams in their approach for delivery of the Accessible Travel Framework

The programme of NHS reform will consider the recommendation that transport should be built in as an integral part of the care pathway.

Whilst the Transport (Scotland) Act was implemented in 2019, sections 120 and 121 required secondary legislation to be enacted. This secondary legislation was enacted and came into effect on 1 October 2023.

We expect reports from Health Boards in Winter 2024. Assessments will be made once these reports are received.

The information requested is not held centrally, it is the responsibility of NHS Health Boards to implement these controls.

The Scottish Government Public Sector Cyber Resilience Framework which applies to all public bodies in Scotland, including health boards and Local Authorities is the framework to which Network Information Systems Regulation 2018 NHS Health Board compliance audits are conducted against.

Controls within the Scottish Government Public Sector Cyber Resilience Framework require that multi-factor authentication is implemented to cover and manage security risk, defending systems against cyber-attack, detecting cyber security events, and minimising the impact of cyber security incidents.

The Scottish Government prepared its draft Transport to Health Plan in 2023, we are continuing to engage with the relevant partners on the commitments contained within the plan. It is expected that the plan will be published by September 2024.

The Scottish Government prepared its draft Transport to Health Plan in 2023, we are currently engaging with the relevant partners on the commitments contained within the plan. It is expected that the plan will be finalised by the end of September 2024. We do not intend to publish the draft plan while it is still being developed.

The Scottish Government remains committed to delivering these two new services. Although the current financial pressures mean that we are unable to provide a delivery timescale, we will continue to undertake preparatory work where possible.

As was the case throughout the COVID-19 pandemic, the Scottish Government continue to listen carefully to the World Health Organization’s advice.

Furthermore, although it is the statutory duty of Local Authorities to manage their school estate, we would be happy to work in partnership with them on this matter.

Although the “Reducing the risks of COVID-19 in schools” guidance has been stood down and there are no current plans to revise it, we recognise the benefits of clean air in preventing COVID-19.

It is the statutory duty of Local Authorities to manage their school estate and it would, therefore, be for them to consider local circumstances and determine if it would be appropriate to allow parents to donate HEPA filters to their schools.

The Scottish Government is committed to ensuring that people with diabetes to receive the best care, treatment and support. Clinical indications for technology required to optimise diabetes control are very different for people with type 2 diabetes compared to those with type 1 diabetes.

At present, clinical guidelines indicate that technology is required in only a select cohort of individuals with type 2 diabetes and we are monitoring provision of this via prescribing data.